Success Metrics

Clinical Success Rate
45.5%

Based on 5 completed trials

Completion Rate
45%(5/11)
Active Trials
3(21%)
Results Posted
160%(8 trials)
Terminated
6(43%)

Phase Distribution

Ph phase_3
2
14%
Ph phase_1
4
29%
Ph phase_2
8
57%

Phase Distribution

4

Early Stage

8

Mid Stage

2

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
4(28.6%)
Phase 2Efficacy & side effects
8(57.1%)
Phase 3Large-scale testing
2(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

45.5%

5 of 11 finished

Non-Completion Rate

54.5%

6 ended early

Currently Active

3

trials recruiting

Total Trials

14

all time

Status Distribution
Active(3)
Completed(5)
Terminated(6)

Detailed Status

Terminated6
Completed5
Active, not recruiting3

Development Timeline

Analytics

Development Status

Total Trials
14
Active
3
Success Rate
45.5%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (28.6%)
Phase 28 (57.1%)
Phase 32 (14.3%)

Trials by Status

completed536%
terminated643%
active_not_recruiting321%

Recent Activity

3 active trials
Showing 5 of 14
terminatedphase_1

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

NCT04903197
active_not_recruitingphase_3

Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05350072
active_not_recruitingphase_3

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

NCT05349214
completedphase_2

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade

NCT03217422
active_not_recruitingphase_2

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT03827798
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT04903197Phase 1

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Terminated
NCT05350072Phase 3

Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Active Not Recruiting
NCT05349214Phase 3

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Active Not Recruiting
NCT03217422Phase 2

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade

Completed
NCT03827798Phase 2

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Active Not Recruiting
NCT03656562Phase 2

Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients

Completed
NCT03400176Phase 1

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Terminated
NCT02962895Phase 2

Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

Completed
NCT03287414Phase 2

Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis

Terminated
NCT01930175Phase 2

Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris

Terminated
NCT02149420Phase 2

PD of VAY736 in Patients With Primary Sjögren's Syndrome

Completed
NCT02038049Phase 2

A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis

Terminated
NCT02675803Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis Patients

Completed
NCT02137889Phase 1

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients

Terminated

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14